First Trust Direct Indexing L.P. Sells 3,403 Shares of Grifols, S.A. (NASDAQ:GRFS)

First Trust Direct Indexing L.P. lessened its stake in Grifols, S.A. (NASDAQ:GRFS – Free Report) by 4.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,936 shares of the biotechnology company’s stock after selling 3,403 shares during the period. First Trust Direct Indexing L.P.’s holdings in Grifols were worth $486,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Grifols by 11.0% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 166,823 shares of the biotechnology company’s stock worth $1,229,000 after acquiring an additional 16,517 shares during the last quarter. Regal Partners Ltd purchased a new stake in Grifols in the 4th quarter worth $678,000. CI Private Wealth LLC bought a new stake in shares of Grifols in the 4th quarter worth about $93,000. Thomas White International Ltd. increased its holdings in shares of Grifols by 40.6% in the 4th quarter. Thomas White International Ltd. now owns 61,525 shares of the biotechnology company’s stock worth $523,000 after buying an additional 17,777 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Grifols in the 4th quarter worth about $390,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Get Grifols alerts:

Grifols Stock Performance

NASDAQ:GRFS opened at $9.45 on Friday. Grifols, S.A. has a 52 week low of $5.71 and a 52 week high of $10.80. The firm has a 50 day moving average of $8.89 and a 200 day moving average of $8.53. The company has a debt-to-equity ratio of 1.22, a current ratio of 2.31 and a quick ratio of 0.70.

Analyst Ratings Changes

Several brokerages recently commented on GRFS. StockNews.com began coverage on shares of Grifols in a report on Thursday, May 18th. They set a “hold” rating on the stock. Morgan Stanley raised shares of Grifols from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 12th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $10.58.

Grifols Company Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.

Further Reading

• Five stocks we like better than Grifols
• MarketBeat Week in Review – 7/10 – 7/14
• Wells Fargo’s Earnings, Why Markets Are Loving The Stock
• Citigroup Leads Banking Earnings, What’s Next?
• BlackRock Kicks Off Financials Earnings Season, Gauge To Markets
• JPMorgan Chase Is In Reversal But Don’t Chase It Higher 

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.